BMY — Bristol-Myers Squibb Co Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareConservativeLarge CapNeutral

Annual cashflow statement for Bristol-Myers Squibb Co, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	3,460	-8,995	7,014	6,345	8,040
Depreciation
Deferred Taxes
Non-Cash Items	720	10,701	1,153	1,412	1,262
Unusual Items
Other Non-Cash Items
Changes in Working Capital	3,065	983	-1,253	-2,229	-1,914
Change in Accounts Receivable
Change in Inventories
Change in Accounts Payable
Change in Taxes Payable
Change in Other Liabilities
Net Change in Other Assets & Liabilities
Cash from Operating Activities	8,067	14,052	16,207	13,066	13,860
Capital Expenditures	-836	-753	-973	-1,118	-1,209
Purchase of Fixed Assets
Other Investing Cash Flow Items	-8,934	-10,106	435	56	-1,086
Acquisition of Business
Sale of Business
Sale/Maturity of Investment
Purchase of Investments
Cash from Investing Activities	-9,770	-10,859	-538	-1,062	-2,295
Financing Cash Flow Items	-53	542	641	984	27
Other Financing Cash Flow
Total Cash Dividends Paid
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	7,621	-1,151	-16,224	-16,962	-9,416
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	5,909	2,153	-657	-4,991	2,194